KLOW peptide is a four-part research blend studied through its single-component tissue-repair literature

In plain English

KLOW peptide is the name given to a research-only vial that contains four distinct peptides dissolved together: KPV, GHK-Cu (copper tripeptide), BPC-157 and TB-500. None of the four is FDA-approved. The vial is not a drug — it is a laboratory research co-formulation. The typical research vial holds 80 mg total, split roughly 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500 and 10 mg KPV.

Each of the four peptides has been studied on its own — in cells, in rodents, and in a few early human pilots. Those individual studies show tissue-repair, anti-inflammatory and wound-healing effects in model systems. What has never been studied is the four peptides together: no controlled trial of the KLOW blend itself exists, so any claim about the combined effect is extrapolation from single-component work.

This site is a reading room for the component literature. Every finding is attributed to the specific peptide it comes from, labeled with the study that measured it, and separated clearly from the community-reported anecdotes on the KLOW effects page.

What is KLOW peptide

KLOW peptide is a research co-formulation — four chemically distinct peptides co-dissolved in a single lyophilized vial at fixed mass ratios. The canonical research-vial composition is 80 mg total: GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, KPV 10 mg. The peptides do not form a single chemical complex; they remain separate molecules in solution.

The four arms cover largely non-overlapping nodes of a tissue-repair signaling network. KPV (Lys-Pro-Val, the C-terminal tripeptide of alpha-MSH) suppresses NF-kB (a transcription factor central to inflammatory gene expression) and MAPK inflammatory signaling with tissue-selective uptake via the PepT1 transporter (a transporter that pulls small peptides into inflamed gut epithelial cells and macrophages) ^[3]. GHK-Cu (Glycyl-L-Histidyl-L-Lysine complexed to a copper ion) is the mass-dominant component — about 62.5% by mass — and acts at the transcriptome level toward matrix synthesis, antioxidant defense and DNA repair while supplying copper for the collagen-crosslinking enzymes ^[4][5]. BPC-157 (Body Protection Compound 157, a 15-amino-acid peptide from a gastric-juice protein) drives the VEGFR2/PI3K/Akt/eNOS angiogenic cascade (the pathway that forms new blood vessels in injured tissue) and upregulates the growth-hormone receptor in tendon fibroblasts ^{[2][9][10][11]}. TB-500 (the synthetic heptapeptide Ac-LKKTETQ, marketed as the actin-binding region of thymosin beta-4) sequesters G-actin, a step linked to cell migration and re-epithelialization ^[1].

KLOW

KLOW is not a single molecule. It is a co-formulation name — a shorthand for the four-arm combination. No single CAS number, UNII or PubChem identifier exists for the blend, because it is a mixture rather than a defined chemical substance. Each component has its own identifier; the blend does not.

Crucially, the KLOW blend itself has never been tested in any controlled study — against monotherapy, against any subset of the four, or against placebo. Every statement about how the four arms interact is a mechanistic extrapolation from the single-component literature. This is the one editorial point this site will not soften: the evidence base is per-component, not per-blend.

KLOW blend

The KLOW peptide blend draws its tissue-repair rationale from four distinct research lines. In BPC-157 studies, a fully transected rat Achilles tendon healed faster across biomechanical, functional, microscopic and macroscopic measures at doses of 10 μg, 10 ng or 10 pg per rat administered intraperitoneally ^[2]. Separate BPC-157 work showed improved tendon-to-bone healing after Achilles detachment ^[9], improved medial collateral ligament healing in rats ^[10], and increased tendon fibroblast outgrowth, survival and migration in vitro via the FAK-paxillin pathway ^[11].

For the TB-500 arm: in a rat full-thickness wound model, topical or intraperitoneal thymosin β4 — the full-length native protein from which the TB-500 fragment is derived — increased re-epithelialization by 42% at 4 days and up to 61% at 7 days versus saline, with increased wound contraction (≥11% by day 7) and raised collagen deposition and angiogenesis; as little as 10 pg stimulated keratinocyte migration 2–3-fold ^[1].

For the KPV arm: nanomolar KPV reduced NF-kB and MAPK activation and pro-inflammatory cytokine secretion in human epithelial and immune cells, and oral KPV reduced the severity of DSS- and TNBS-induced colitis in mice ^[3]. For GHK-Cu: topical GHK-Cu increased collagen production in 70% of treated women versus 50% for vitamin C and 40% for retinoic acid, and plasma GHK levels decline from about 200 ng/mL at age 20 to about 80 ng/mL by age 60 ^[4].

All four findings are component-level. None was produced in a combined KLOW experiment.

KLOW peptide blend

What the KLOW peptide blend represents, stated precisely: four peptides whose individual mechanisms address cytokine suppression, matrix remodeling, vascular supply and cytoskeletal mobility as complementary steps in a tissue-repair cascade. The combination rationale is mechanistically coherent. The combination evidence does not yet exist.

KLOW peptide benefits

Reported benefits — drawn from what the single-component studies have measured, attributed to each component:

From BPC-157 studies in rodents: accelerated Achilles tendon healing ^[2], tendon-to-bone repair ^[9], ligament healing ^[10], tendon fibroblast proliferation and survival ^[11], and organ-protective effects in experimental acute pancreatitis ^[15].

From thymosin β4 / TB-500 studies: accelerated re-epithelialization (+42% at 4 days, +61% at 7 days in a full-thickness rat wound model), increased wound contraction and collagen deposition ^[1].

From KPV studies: NF-kB and MAPK suppression in human intestinal epithelial cells, reduced TNF-α, IL-6 and IL-1β secretion, reduced severity of experimental colitis ^[3].

From GHK-Cu studies: stimulation of collagen, dermatan sulfate, chondroitin sulfate and decorin synthesis; demonstrated improvement in skin laxity, fine lines and wrinkle depth in placebo-controlled clinical work; broad transcriptomic shifts toward matrix synthesis, antioxidant defense and DNA repair at low-nanomolar concentrations ^[4][5].

None of these benefits has been demonstrated for the combined KLOW blend. Each derives from a monotherapy study. Attribution to the blend as a whole is extrapolation.

For community-reported effects — what people in research-use communities describe observing — see the KLOW effects page, where those accounts are presented as anecdotal, not clinical evidence.

Safety and the untested combination

Three safety points the literature makes clearly:

The blend is untested. No controlled safety or efficacy study has ever examined the four-peptide KLOW combination. The BPC-157 human pilot data are limited: a 2025 study (Lee & Burgess) administered intravenous BPC-157 at 10 mg and 20 mg to two healthy adults and observed no adverse events and no measurable changes in cardiac, hepatic, renal, thyroid or glucose biomarkers ^[6]. That is n=2, a single-session IV infusion, and not a blend study.

TB-500 and anti-doping. Thymosin beta-4 is named on the WADA Prohibited List (S2 — peptide hormones, growth factors), banned at all times in and out of competition. Because TB-500 is the synthetic fragment of thymosin beta-4 and one of the four KLOW components, using the blend implicates anti-doping rules in any athletic-research context.

Pro-angiogenesis and the cancer caution. Three of the four components — BPC-157, TB-500/thymosin beta-4 and GHK-Cu — promote new blood-vessel growth through documented angiogenic mechanisms. Solid tumors depend on angiogenesis for their blood supply; this is a theoretical mechanistic caution for anyone with an active or recent cancer, not a clinical finding from a human study.

Full safety and caution detail, with citations, is on the KLOW effects page.